Table 4.
One-way sensitivity analysis in the posthospital population
| Cost difference (£) | QALY difference | ICER (£/QALY) | Probability cost-effective* | |
| Varying the rate ratio | ||||
| Best-case NIV | +£4855 | +0.596 | £8146 | 100% |
| Worst-case NIV | +£4715 | −0.220 | Dominated | 1.1% |
| Base case | +£4799 | +0.424 | £11 318 | 99.9% |
| Best case ‘Western’ settings NIV† | +£4765 | +0.539 | £8979 | 100% |
| Worst-case ‘Western’ settings NIV† | +£4687 | −0.215 | Dominated | 0% |
| Change in utility on NIV | ||||
| +0.20 utility | +£4799 | +1.005 | £4763 | 100% |
| +0.10 utility | +£4799 | +0.714 | £6707 | 100% |
| +0.05 utility | +£4799 | +0.571 | £8385 | 100% |
| −0.05 utility | +£4799 | +0.280 | £17 104 | 71.1% |
| −0.10 utility | +£4799 | +0.135 | £35 526 | 5.4% |
| −0.20 utility | +£4799 | −0.158 | Dominated | 0% |
| Varying duration of effect | ||||
| 2 years | +£4813 | +0.218 | £22 078 | 26.0% |
| 5 years (base case) | +£4799 | +0.424 | £11 318 | 99.9% |
| 10 years (model horizon) | +£4172 | +0.535 | £7798 | 99.9% |
| Alternate model time horizon | ||||
| 2 years | +£919 | +0.073 | £12 589 | 78.9% |
| 5 years | +£2187 | +0.260 | £8408 | 99.5% |
| 10 years (base case) | +£4799 | +0.424 | £11 318 | 99.9% |
| 20 years | +£5763 | +0.484 | £11 914 | 99.4% |
| Alternate Mortality and readmission risk | ||||
| Lower risks from Bucknall et al 14 | +£3715 | +0.173 | £21 473 | 39.34% |
| Doubling all mortality risks13 15 | +£3953 | +0.400 | £9883 | 99.9% |
*Cost-effective at £20 000/QALY.
†Western studies included studies from Italy, Poland, the Netherlands, Germany, and the UK.
ICER, incremental cost-effectiveness ratio; NIV, non-invasive ventilation; QALY, quality-adjusted life year.